Phase II study of Panitunumab plus Cetuximab in pretreated in patients with metastatic colorectal cancer
Ontology highlight
ABSTRACT: Primary objectives: Assess the efficacy of panitumumab in combination with Trifluridine- Tipiracile vs standard third line therapy (Trifluridine-Tipiracile) as measured by PFS
Primary endpoints: PFS: defined as the time from randomization to the earliest documented disease progression or death due to any cause
DISEASE(S): Mcrc,Tumore Del Colon-retto Metastatico,Gastrointestinal Neoplasms Malignant And Unspecified
PROVIDER: 2538100 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA